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Abstract
Objective: Recently, the promising potential of fibroblast transplantation has become a novel modality for skin 
rejuvenation. We investigated the long-term safety and efficacy of autologous fibroblast transplantation for participants 
with mild to severe facial contour deformities.          
Materials and Methods: In this open-label, single-arm phase IIa clinical trial, a total of 57 participants with wrinkles 
(n=37, 132 treatment sites) or acne scars (n=20, 36 treatment sites) who had an evaluator’s assessment score of 
at least 2 out 7 (based on a standard photo-guide scoring) received 3 injections of autologous cultured fibroblasts 
administered at 4-6 week intervals. Efficacy evaluations were performed at 2, 6, 12, and 24 months after the final 
injection based on evaluator and patient’s assessment scores.
Results: Our study showed a mean improvement of 2 scores in the wrinkle and acne scar treatment sites. At sixth 
months after transplantation, 90.1% of the wrinkle sites and 86.1% of the acne scar sites showed at least a one grade 
improvement on evaluator assessments. We also observed at least a 2-grade improvement in 56.1% of the wrinkle 
sites and 63.9% of the acne scar sites. A total of 70.5% of wrinkle sites and 72.2% of acne scar sites were scored as 
good or excellent on patient assessments. The efficacy outcomes remained stable up to 24-month. We did not observe 
any serious adverse events during the study. 
Conclusion: These results have shown that autologous fibroblast transplantation could be a promising remodeling 
modality with long-term corrective ability and minimal adverse events (Registration Number: NCT01115634).     
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Introduction
Fibroblasts are the predominant cells of connective 
tissue that synthetize and organize collagen and other 
extracellular matrix (ECM) proteins. Furthermore, 
Fibroblasts secrete soluble cytokines and growth factors 
such as transforming growth factor-beta (TGF-β), 
keratinocyte growth factor (KGF), vascular endothelial 
growth factor (VEGF), and insulin-like growth factor 
(IGF) to maintain the structural integrity of the skin (1-3).
Skin aging is a complex, multifactorial process defined 
by progressive loss in skin integrity and function (4). The 
size, amount, and potency of fibroblasts chronologically 
decline due to natural cellular and molecular events such 
as reductions in TGF-β, micro-environment alterations, 
and Notch signaling disruption (5-8). Aged-fibroblasts 
secrete higher levels of matrix metalloproteinase that 
degrade collagen fibrils (9). Since a reciprocal mechanical 
force between fibroblasts and collagen fibrils is necessary 
for continuous collagen synthesis, degraded collagen 
fragments cause a breakdown in the tissue cycle (3, 10, 11).
On the other hand, destruction of fibroblasts and 
consequent collagen loss seen in acne scars result from 
a healing defect after local and systemic inflammation. 
This defect leads to destruction of the dermal structures 
with subsequent fibrosis (12, 13). Acne scars occur in 95% 
of acne participants even during standard treatments, in 
